Results 141 to 150 of about 116,628 (279)

Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1662-1674, October 2026.
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs   +10 more
wiley   +1 more source

Herpes Zoster In A 3 Month Old Infant

open access: yesIndian Journal of Dermatology, 1998
A case of herpes zoster in a 3 month old female infant is reported. The patient suffered from varicella 1 month prior to onset of herpes zoster, following varicella of mother.
Gangopadhyay D N, Barbhuiya J N, Dey S K
doaj  

Atopic dermatitis is associated with herpes zoster in adults - A matched cohort study using electronic health records data in England. [PDF]

open access: yesJ Dtsch Dermatol Ges
Summary Background and objectives Some atopic dermatitis (AD) treatments have been linked to an increased risk of herpes zoster (HZ). Limited evidence suggests an independent association between atopic dermatitis and herpes zoster. The study aimed to investigate the association between atopic dermatitis and herpes zoster in the UK and to explore the ...
Schober AK   +4 more
europepmc   +2 more sources

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

open access: yesJournal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Membrane‐Permeable Nucleoside T‐1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides

open access: yesChemistry – A European Journal, Volume 32, Issue 34, 11 September 2026.
Favipiravir (T‐705) and the non‐fluorinated counterpart (T‐1106) are antiviral agents that inhibit the RNA‐dependent RNA polymerase (RdRp) of various RNA viruses. The antiviral efficacy of nucleoside analogues is strongly dependent on their intracellular activation by cellular kinases to produce their corresponding triphosphate metabolites (T‐705‐RTP ...
Chris Meier   +7 more
wiley   +1 more source

Closed‐Loop Decoding and Intervention of Pain: A Novel BMI Strategy Integrating θ‐Band Detection and Mechano‐Electro‐Biological Coupled Hydrogels

open access: yesAdvanced Science, Volume 13, Issue 52, 18 September 2026.
A closed‐loop brain–machine interface with a PFAPT hydrogel electrode identifies prefrontal θ‐band as a neuropathic pain biomarker. The hydrogel enables stable 28 d ECoG recording and delivers θ‐triggered cortical stimulation, alleviating pain and affective behaviors in rats via bidirectional regulation of inflammation and central sensitization ...
Yun Ji   +17 more
wiley   +1 more source

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2353-2370, September 2026.
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig   +25 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez   +17 more
wiley   +1 more source

Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges

open access: yes, 2016
Lara el Hayderi, Fany Colson, Bita Dezfoulian, Arjen F Nikkels Department of Dermatology, CHU du Sart Tilman, University Hospital of Liège, Liège, Belgium Abstract: As TNF-α is a major factor in the immune defense against herpes ...
Dezfoulian B   +3 more
core  

Home - About - Disclaimer - Privacy